Breaking News

Covishield Vaccine Production Surpasses 1 Billion

November 30, 2021 • 1:01 pm CST
(Precision Vaccinations News)

Serum Institute of India (SII) announced on November 26, 2021, it has resumed exporting its COVID-19 vaccine to COVAX, which distributes vaccines to low- and middle-income countries.

The resumption of Covishield vaccine exports is linked to SII surpassing its original target to produce 1 billion doses by the end of 2021.

SII stated in a press release it has reached this milestone.

Adar Poonawalla, CEO of SII, said in a press release, "I want to thank our workforce for their superhuman efforts in achieving this major milestone, with 1 billion doses of COVISHIELD produced. We started to invest at-risk in COVID-19 vaccine production back in March 2020."

"It's a huge moment to begin exports again, for us, our partners at COVAX and the low- and middle-income countries we support."

"The world has largely depended on the low-cost, high-quality pharmaceuticals and vaccines that India has traditionally exported, so we are delighted to support the global vaccination effort once more."

 CoviShield is made from a weakened version of a common cold virus (adenovirus). In addition, genetic material has been added, which is used to make proteins from the SARS-CoV-2 coronavirus called Spike glycoprotein.

This COVID-19 vaccine was co-developed by AstraZeneca Plc and the University of Oxford and is the same formulation as the Vaxzevria (AZD1222) vaccine.

The WHO has included Covishield in its emergency use listing.

Our Trust Standards: Medical Advisory Committee